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Mood Disorders and BDNF Relationship with Alcohol Drinking 
Trajectories among PLWH Receiving Care
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1School of Integrated Science and Humanity, Florida International University, Miami, FL, USA
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Abstract
Background—Despite the excessive rates of Hazardous Alcohol Use (HAU) among people 
living with HIV (PLWH), although largely speculated, psychological and physiological 
components associated with HAU, has not been actively measured. Therefore, the present study 
was geared toward determining: 1) the rates of mood disorders and its relationship with HAU, and 
2) to assess the impact of Brain Derived Neurotrophic Factor (BDNF), a well-known regulator of 
alcohol and mood disorders.
Methods—For this study, participants of the longitudinal PADS Study n=400, were followed 
over time. Alcohol use (Alcohol Use Disorders Identification Test –AUDIT- and the Alcohol 
Dependence Scale –ADS) and moods (depression, anxiety, and stress) were assessed repeatedly.
Results—A cluster analyses shows three distinctive trajectories. The first one, revealed a group 
with increased drinking (Cluster 1: n=140), constant alcohol intake (Cluster 2: n = 60), and one 
with decreased consumption (Cluster 3: n =120).
Analyses discovered higher AUDIT scores across the clusters with Cluster 1 being followed by 
Clusters 2 and 3 (1: 14.5 ± 8 vs. 2=8.7 ± 7.5 vs. 3= 6.6 ± 4.2, p = 0.001). Women in Clusters 1 and 
2 had higher levels of stress (1:21 ± 7.5; 2:19.3 ± 7) and lower BDNF levels (7904 ± 1248 pg/ml 
and 10405 ± 909 pg/mL) than their counterparts in Cluster 3 (PSS: 3: 16.6 ±5, p = 0.02 BDNF: 
10828 ± 1127 pg/mL, p = 0.08). Men in Cluster 1 differed in terms of stress (19.8 ± 7 vs. 21 ± 7.5 
score) and BDNF levels (Cluster 1: 5204 ± 818 vs. Cluster 2: 7656 ± 843 pg/ml, p = 0.002) but 
not in the number of years living with HIV. The proportion of subjects with multiple mood 
comorbidities was disturbingly higher (26%), and all were members of Cluster 1. Multiple logistic 
regression analyses indicated that participants reporting high relative to low levels of perceived 
stress, dual mood comorbidity, altered BDNF levels and low income increased the likelihood of 
being a member of Cluster 1.
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Conclusion—This study found that stress and overlaying psychiatric comorbidities are linked 
with persistent alcohol use. Findings suggest that BDNF and social support seems to be a logical 
target as it seems to be the bridge linking mood disorders and alcohol consumption.
Keywords
HIV; Hazardous alcohol; Alcohol trajectories; BDNF; Mood; Anxiety; Depression; Stress; Gender
Introduction
While in the beginning of the HIV epidemic concerns were primarily related to drug 
addiction. Through the years hazardous alcohol use has occupied a prominent place in the 
HIV/AIDS epidemic [1–6]. Although HAU is a topic of theoretical interest for both, 
researchers and health care providers, given its excessive rates (40–80%) [2–6], little 
information is available with regards to the underpinnings mediating the excessive rates 
among PLWH. Such information can help in the development of health policy tools, but it 
can also guide the design of successful treatment approaches, which, so far, have produced 
only limited evidence that such interventions work among PLWH [7].
One mechanism that could explain the excessive rates of HAU among PLWH is Brain 
Derived Neurotrophic Factor (BDNF), a “Miracle Grow” chemical for the brain that could 
be directly affected by the HIV virus, as well as by epigenetic factors. Unequivocal 
experimental and clinical evidences, causally linked alterations of BDNF signaling with the 
pathophysiology of alcohol abuse [8–11]. In animal models, BDNF depletions provoked 
anxiety-like behaviors, resulting in increased alcohol intakes, which could be rescued by 
BDNF co-infusion [11]. BDNF heterozygous mice, which expressed about half as much 
BDNF protein as their wild-type counterparts, displayed increased conditioned place 
preferences and locomotor sensitization to alcohol [10–13]. They also showed prolonged 
alcohol consumption, following a period of abstinence, suggesting that BDNF may decrease 
the rewarding effects of alcohol [13]. In fact, BDNF has been suggested as a predictor of 
relapse. The region of human chromosome 11 containing BDNF has been implicated as a 
susceptibility locus for severe alcohol withdrawal [14]. Activity-dependent activation of 
BDNF has been linked with the neuroadaptation process that occurs in the development of 
alcohol addiction [10,15–17].
As depicted in Figure 1, studies have demonstrated a reciprocal relationship between mood 
disorders and BDNF levels, both in circulation as well as in the brain [18]. Both, acute and 
chronic stress may alter BDNF levels [19,20]. Acute stress caused by immobilization, as 
well as swim-stress tests, increased the levels of BDNF mRNA, suggesting that epigenetic 
mechanisms underlined this response [19,20]. Increased BDNF expression may represent a 
protective mechanism in response to stress. Conversely, reduced BDNF levels after 
exposure to repetitive and chronic stress has been observed and appears to represent an 
adjustment of this mechanism [21–23]. The relationship between stressful life events and 
hazardous alcohol use is also recognized in humans. Epidemiological studies have 
consistently demonstrated that a variety of stressors lead to drinking. PLWH are being 
exposed to a myriad of societal (poverty) and HIV related stressors (stigma). However, the 
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relationship between BDNF, stress, and alcohol use has not been assessed among PLWH. 
Such information is of high relevance for the design of future interventions.
The World Health Organization foresees depression as becoming the leading cause of 
worldwide disability [24]. Nearly one-third of people with major depression also have an 
alcohol problem, according to one major study conducted by the National Institute on 
Alcohol Abuse and Alcoholism [25]. Of concern, depression is a widespread problem 
among PLWH. Heckman et al. found that among PLWH, 29% had moderate to severe 
depression, with an additional 31% having mild depression [26]. As many as half of 
participants enrolled in the Gay Men’s Health Crisis and the America’s Research on Older 
Adults with HIV, had depression. In many cases depression may be the first one to occur, 
and in others it emerged after HIV diagnosis [27]. Unfortunately, people struggling with 
depression and HIV are also likely to struggle with alcohol abuse and vice versa [28]. It 
seems that by altering serotonin, BNDF is the bridge that connects alcohol and depression.
On the same track, Pandey and colleagues have demonstrated that BDNF deficiency induced 
anxiety in rats, followed by increased consumption of alcohol [12]. By blocking BDNF 
levels in the amygdala, the researchers were able to trigger both anxiety like behaviors and 
alcohol dependence. Noteworthy, this area of the brain deals with stressful events, as well as 
with rewarding experiences of drugs and alcohol. Recently, You Chang demonstrated that 
high alcohol-drinking rats had innately higher anxiety levels, along with less BDNF 
expression [29]. When levels of BDNF in the central and medial amygdala were restored to 
normal, anxiety and alcohol consumption diminished, suggesting that the deficits in BDNF 
signaling were the key in these disorders. In humans, anxiety is frequently measured using 
the State Trait Anxiety inventory, a test that emerged from the distinction between anxiety 
as a mood state that is temporary, and anxiety as a stable attribute. Studies suggest that 
individuals with trait anxiety use alcohol as a mechanism to cope with the symptoms. 
According to these postulates, trait anxiety levels are positively associated with alcohol 
dependence [30–32].
Another mood disorder that is highly prevalent among PLWH, and that has been associated 
with alcohol use, is stress [28,33,34]. In terms of health, any event that exerts a physical, 
emotional, or cognitive demand on the individual is considered a stressor. Yet, when it 
occurs in quantities greater than the individual’s capacity to handle, pathological changes 
can occur [34]. Stress is considered a significant factor in the initiation and continuation of 
HAU [35]. Researchers have postulated that the body’s response to stress most likely plays a 
role in the vulnerability of the initiation of HAU, and in relapse in those under treatment 
[33–35]. This relationship probably is mediated, at least in part, by common neurochemical 
systems, such as the serotonin, dopamine, and opiate peptide systems, as well as the 
Hypothalamic-Pituitary-Adrenal (HPA) axis [36–38]. The basic mechanisms are still under 
investigation, but involve release of the stress hormones (i.e. corticosterone), causing 
alterations in BDNF, the serotonin pathways, and neurogenesis. Further in the study, these 
animals showed increased alcohol self-administration, regardless of whether the stressful 
experiences continued during the length of the study or had ended weeks earlier [39]. 
Remarkably, both acute and chronic stress resulted in an aberrant regulation of BDNF 
signaling in the hippocampus, prefrontal cortex, and amygdala [21–23]. The initial response 
Míguez-Burbano et al. Page 3
J Alcohol Drug Depend. Author manuscript; available in PMC 2015 October 21.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
is a compensatory elevation of BDNF to prevent damage, which is followed by a drop in 
BDNF levels. BDNF deficits may lead to an increased preference for ethanol.
In summary, it has been clearly established in animal models that anxiety, depression, and 
stress, could trigger alcohol use; however, to the best of our knowledge, these relationships 
have not been explored among PLWH. Examining their specific relationships with the 
excessive rates of alcohol use in this population is of critical importance. Accordingly, the 
dual goal of this research is: 1) to investigate the often assumed relation between alcohol use 
and mood disorders, and 2) to determine if similar conclusions can be derived in humans. In 
addition, to examine HAU at the neurochemical level (BDNF) in a cohort study of PLWH 
receiving care in South Florida, a region that has been disproportionately affected by the 
HIV epidemic. Our long-term goal is to inform clinical intervention efforts aiming to reduce 
the deleterious effects of HAU in PLWH.
Methods
Study population
Data was collected in South Florida, as part of the Platelets Mediating Alcohol and HIV 
Damage Study (PADS). All subjects signed both, written informed consent and HIPAA 
forms. The study consists of 400 PLWH, who were at least 18 years old and under regular 
care at primary open-access public health systems in Miami. Subjects with major 
comorbidities were not eligible: CNS opportunistic infection, head injury with or without 
loss of consciousness, tumors, major psychiatric disease, developmental disorders, severe 
malnutrition, or confirmed cardiovascular or immune based disease, (i.e., malignancies, 
autoimmune diseases, arthritis). To reduce the confounding effects of liver disease and/or 
illegal drug use, we also excluded injection and dependent drug users.
Alcohol drinking
At each visit, using a non-judgmental interview style, participants was asked about alcohol 
intake in the past six months, using the Alcohol Use Disorders Identification Test (AUDIT) 
and the Alcohol Dependence Scale (ADS) [40–42]. Participants were asked to report a 
serving size using models of 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of liquor. 
Alcohol consumption scores were computed by averaging cross products of quantity and 
frequency of beer/wine and hard liquor. Then, based on the National Institute of Alcohol 
Abuse and Alcoholism criteria, the sample was dichotomized in two groups: hazardous (men 
who reported >14 drinks/week or >4 drinks in one day, and women who reported >7 drinks/
week or >3 drinks in one day) or non-hazardous alcohol users, for those who reported fewer 
drinks. Participants who drank more than five standard drinks in a given day were 
considered binge drinkers [43].
Participants’ assessment protocol
Those participants who expressed a willingness to participate and that provided written 
informed consent, as well as a medical release, were consecutively enrolled and followed for 
a period of 6 months. Research staff who were trained in social and medical sciences fields, 
Míguez-Burbano et al. Page 4
J Alcohol Drug Depend. Author manuscript; available in PMC 2015 October 21.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
and supervised by the research coordinator and the licensed clinical psychologists, collected 
information using structured questionnaires.
Depression
The BDI-II was completed by a trained assessor, and results were further checked by a 
professional, to ensure quality control. The BDI is one of the most widely used instruments 
to screen and to measure the intensity of depression, and has been translated into several 
languages [44]. The BDI contains 21 items that can be answered on a 4-point scale. The 
total score, which ranges from 0–63, is obtained from the sum of the scores of the 21 items. 
A total score of 0–9 is considered to be normal, 10–18 corresponds to mildly depressed, 19–
28 equals moderate depression, and scores above 29 are considered severe depression.
State-trait anxiety inventory form X
Trait anxiety was measured with Spielberger’s State-Trait Anxiety questionnaire (STAI) 
[45,46]. STAI is composed of two scales for assessing levels of state and trait anxiety. For 
the 20-item state anxiety scale participants have to rate each question on a 4-point Likert 
scale (from “almost never” to “almost always”). Scores of 20–39 were indicative of low 
anxiety; 40–59 moderate, and from 60–80 severe anxiety.
Perceived stress scale
Developed by Cohen and colleagues, this instrument is a global measurement of stress. 
Participants responded to 10 questions, to assess whether they perceive their lives as 
unpredictable, uncontrollable or overloaded [47,48]. The PSS is a widely used scale to 
measure stress in chronic conditions, and therefore we deemed appropriate to be used in 
PLWH. The PSS is not a diagnostic test, and therefore there are no cut-offs to determine 
stressed individuals. Accordingly, stress levels were analyzed by quartiles.
Brain derived neurotrophic factor (BDNF)
Prior studies have demonstrated that plasma levels of BDNF, although different from levels 
in Cerebrospinal Fluid (CSF), are correlated with CSF in Central Nervous System (CNS) 
diseases [49,50]. Due to this association, circulating levels of BDNF were selected for 
analyses. Plasma BDNF levels were measured using a commercially available ELISA kit 
(R&D System), according to the manufacturer’s instructions. Briefly, 50 μl of standard and 
20-fold diluted samples were pipetted into wells of a 96-well immunoplates. An enzyme-
linked monoclonal antibody specific for BDNF was added to the wells. Following a wash to 
remove any unbound antibody-enzyme reagent, a substrate solution was added to the wells, 
and color developed in proportion to the amount of BDNF bound in the initial step. The 
color development was stopped, and the intensity of the color was measured. BDNF 
concentration in plasma was calculated based on a standard curve. The minimum detectable 
dose of BDNF is typically less than 60 pg/mL.
Potential confounders
A number of plausible confounders were measured, and included age, sex, race/ethnicity, 
years of education, and smoking status. Overall, nutritional status was determined by 
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measurements of serum albumin levels. In addition, HIV associated variables were assessed, 
as time since diagnosis, time receiving antiretroviral therapy, HIV-specific clinical history, 
CD4 and Viral load (AMPLICOR HIV-1 monitor test, Roche Diagnostics, Branchburg, NJ).
Statistical analyses
The normality of the distribution of primary outcomes of interest was examined with a 
normal probability plot. Descriptive statistics, such as minimum, maximum, median, and 
mean with SD were used to summarize the data, as well as to detect outliers and missing 
values. Group comparisons were assessed using the chi-square test for categorical variables, 
two sample Student’s t-test for normally distributed continuous variables, and the Wilcoxon 
rank sum test for non-parametrically distributed continuous variables. We employed the 
Bonferroni correction, because of the multiple comparisons. Alcohol use variables, BDNF, 
BDI, STAI and PSS were assessed both as continuous as well as categorical variables.
Level of alcohol use has been the most frequently modeled dependent variable in the extant 
literature on alcohol, and was selected to analyze drinking trajectories. To examine potential 
mediators, regression models were employed, using the interaction terms as independent 
variables and BDI and Anxiety, and PS scores as dependent variables. All plausible 
predictors used on multivariable regression models were dichotomized, to give equal weight 
to the different variables associations. Psychological measures were dichotomized in 
accordance to values for distress (PSS >23), mild depression (Beck > 20) and anxiety (state> 
35, and trait anxiety > 35) years living with HIV by 5 years, CD4 counts < 200 yes/no, viral 
load detectable yes/no, therapy yes/no, smoking yes/no, sociodemographics and therapy for 
mood disorders yes/no. Analyses were controlled by age, cigarette smoking, HIV, BMI, time 
of HIV diagnosis and treatment. The validity of model assumptions was evaluated using 
analysis of residuals. P values less than 0.05 (2-tailed) were considered significant. Data 
analyses were performed using SPSS version 18.
Ethics
The study was approved by Florida International University and the University Of Miami 
School Of Medicine Committee for the protection of the rights of human subjects.
Results
Group characteristics
The 400 participants included 37% females and 63% males, ranging in age from 21 to 50 
years (42 ± 6 years). Participants had received a diagnosis of HIV infection typically more 
than a decade before (15 ± 8 years ago range 2–29).
Though among non-HAU over half (55%) never or rarely drank alcoholic beverages 
(Control Group), 34% imbibed at least once a week, typically more than two drinks per 
occasion. HAULWH were actively drinking at the time of assessment an excess of 7 ± 5 
drinks per day. They regularly consumed alcohol on average 4 days a week, and the mean 
total intake was of 31 drinks/week.
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Age, race/ethnicity, sexual orientation for men, education level, and health insurance status 
were not associated with being or not a HAU.
Depression and alcohol use
The average BDI total score was 17.3 ± 12.4 in the “mild depressed” range. Of concern, a 
sizable portion of the group met the criteria for mild (16%), moderate depression (6%) or 
severe depression (6%, with scores of 30 and above). As depicted in Table 1, depression was 
not associated with either socio-economic status or education. Although depression is the 
leading cause of disease burden for women, in our sample differences in the rates of 
depression by gender were not significant (17.7 ± 15.6 ± 12 score, p = 0.1). Importantly, 
depressed participants were more likely to report heavy drinking behavior (OR=2.5; p = 
0.006).
BDNF and depression
There was a wide concentration range of BDNF in circulation from 298 to >20,000 (mean 
8384 ± 6366 pg/ml). BDNF levels differed by gender with women exhibiting the highest 
levels (9958.9 ± 6578 vs. 7470 ± 6068 pg/ml, p = 0.0001). Our data showed that participants 
with BDNF <3,000, were more likely to score in the moderate to severe range of the BDI-II 
(OR=1.7: 95% CI 1–2.99, p = 0.05).
Anxiety and alcohol drinking
Anxiety disorders were also prominent among the sample, with 90% of the PLWH affected. 
The mean score of the group was 42.33 ± 14. S-anxiety scores between 28–50 were reported 
in 46% of the subjects, and 36% had scores above 60. Anxiety scores were similar between 
males and females (39.0 ± 15 vs. 38.7 ± 14, p = 0.8). However, low income individuals were 
5 times more likely to have anxiety scores above 35 than the more economic solvent 
counterparts (OR=4.8 95% CI 2–11.4, p = 0.0001)
Since among the many reasons why anxiety could be developed were the deteriorating 
symptoms of HIV disease, we examined this association. However, neither CD4 nor viral 
load varied between the groups.
At baseline, a positive correlation between alcohol use and higher trait anxiety was observed 
(r = 0.1, p = 0.04). For additional analyses participants were dichotomized above and below 
35. Subjects with low or no anxiety drunk on average one day more per week (3 ± 2.5 vs. 
2.1 ± 2 days, p = 0. 004) and overall more drinks per week (16 ± 1 vs. 12 ± 1 drinks, p = 
0.04).
Perceived stress and alcohol drinking
Mean PS score was 18 (SD = 6.7, median = 20.0, extremes = 15–23) in the 400 participants. 
PS scores did not differ according to gender (18.7 ± 6.8 18.1 ± 6.7, p = 0.5), CD4 (< 200 
counts) or viral load. However, individuals in the lowest income quartile reported 
significantly higher PS scores than the rest of the sample (18.3 ± 6 vs. 15.5± 6.5, p = 0.04).
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Analyses indicated that subjects with high stress levels (top quartile) did not report an earlier 
use of alcohol. The increase of perceived stress coincided with a significant increase in the 
mean levels of drinking per week. As depicted in Table 2, high levels of perceived stress 
were associated with an increase in the frequency of alcohol use (3 vs. 5 drinking days, p = 
0.02), as well as in the number of drinks taking per occasion. These findings indicate that 
greater stress levels were associated with the drinking profile in a dose dependent manner. 
Notably, a significant correlation between PSS and AUDIT was also observed (r = 0.247, p 
= 0.0001).
Since in animal models a decreased Brain-Derived Neurotrophic Factor (BDNF) expression 
and/or function, particularly in hippocampus, have been implicated in the pathophysiology 
of stress-related disorders, we explored such a relationship. While total PSS were not 
significantly associated with BDNF levels, additional analyses indicated a negative 
correlation between BDNF levels and reporting feeling nervous and stressed (r=−0.192; p = 
0.012), in which lower BDNF levels were associated with the PSS. Stratification of data on 
the basis of feeling stress fairly often (scores 3 and 4) revealed a positive correlation 
between low BDNF levels and feeling distressed (scores 3 and 4: 3951 ± 546 vs. scores 0–2: 
5954 ± 668 pg/mL, p = 0.02). Notably, feeling nervous and stressed were also co-related 
with AUDIT scores (r= −0.197, p = 0.003).
Longitudinal analyses
A total of 320 out of 400 subjects completed the follow-up assessment, and have completed 
data for longitudinal analyses. A significant change in depression was noted at the 6-month 
evaluation, as the mean BDI scores decreased by 19% (− 3.0 ± 0.8, p = 0.000). Evaluation of 
STAI, on the contrary, revealed significant increases (2.6 ± 1.1, p = 0.02). Stress scores were 
similar in the two evaluations (−0.7 ± 0.5, p = 0.1).
Even though at first glance the overall group decreased their alcohol intakes from baseline to 
the follow-up visit (−5.9 ± 1 drinks per week), a cluster analyses shows three distinctive 
trajectories. The first one, revealed a group with increased drinking (Cluster 1: n=140), 
constant alcohol intake (Cluster 2: n = 60), and one with decreased consumption (Cluster 3: 
n =120).
These clusters are consistent with prior studies describing 3–4 types of alcohol users: a 
nonuser/low-use class, a chronic or high-use class, and a desisting class. Since BDNF and 
drinking phenotypes differed by gender, we constructed separate models for male and 
females. As depicted in table 3, women in Cluster 1 reported less years living with HIV than 
the other two groups. Women in Clusters 1 and 2 have lower BDNF levels than their 
counterpart in Cluster 3. Women in Cluster 1 and 2 also exhibited higher levels of stress. 
Among men Group 1 differed in terms of stress and BDNF levels, but not in the number of 
years living with HIV. Regarding age, education and income, among women there were no 
significant differences among the 3 classes.
In the 3 trajectory group solution for men, Cluster 1 (both men and women) showed 
moderate increasing in drinking (from 4 to 6.2 drinks per occasion= +2.3 ± 0.6, p = 0.001); 
Cluster 2 showed low desisting in drinking (from 1.2 to 1 drink per occasion p = 0.4). Class 
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3 significant desisting, while reported initial drinking at a similar or even higher level than 
Cluster 1 (6.9 ± 4 drinks per occasion), informed only 2.8 ± 0.2 drinks in a row, at the 
follow-up visit (p = 0.0001).
Surprisingly, analyses uncovered higher AUDIT scores (both men and women) across the 
clusters with Cluster 1 being followed by Clusters 2 and 3 (1: 14.5 ± 8 vs. 2= 6.6 ± 4.2, vs. 
3=8.7 ± 7.5, p = 0.001). In addition, dual diagnoses (anxiety + stress, or depression +stress), 
which were present in 26% of the study population may complicate alcohol use trajectories 
as analyses indicated that they were all members of Cluster 1.
Table 4 summarizes regression results for alcohol drinking at the last visit. Multiple mood 
comorbidities and distress were uniquely associated with increasing alcohol drinking during 
the length of the study. Data indicated that mood and BDNF were independent predictors of 
alcohol use disorders.
Discussion
Several significant findings have emerged from this study. Of concern, our data indicated an 
astonishing prevalence of mood disorders in our study population. In our cohort, as many as 
38% fulfill the criteria for depression and 63% for anxiety (scores >35). This is significantly 
higher than those reported by Pence and colleagues [51], in which 20% had an anxiety 
disorder. Of most concern is the sizable proportion of the samples that have dual or triple 
mood comorbidity (stress, anxiety, depression). However, high rates were not unexpected, 
given that our sample was predominantly formed by minority patients (women, Hispanic 
and African Americans), with lower-than-average incomes. As such, these individuals 
represent an especially vulnerable population. Although, acute and transient stress is not 
harmful, when stress becomes chronic, the body does not return to the basal unstressed level. 
This chronic state while more subtle continues to exert effects on the autonomic system 
leading in the long-run to metabolic abnormalities, insulin resistance, and endothelial 
damage [33–38]. Notably, our data provide novel evidence for the unique effects of low 
BDNF as a prospective risk factor for hazardous alcohol use among PLWH. The cognition 
may also be compromised maintaining this vicious cycle.
It is surprising that the relationship between mood disorders and alcohol use has not 
received more empirical scrutiny. The analyses showed that high levels of perceived stress 
and anxiety, but not depression, are associated with high levels of alcohol use. Self-reported 
symptoms of apathy are quite common among HIV-infected individuals. Given the enduring 
prevalence and clinical significance of negative moods among PLWH, examination of 
malleable processes related to them is relevant from an intervention standpoint.
It is concerning that almost a third of the participants have multiple comorbidities (stress + 
anxiety + depression), revealing that these individuals were in need of treatment for their 
psychiatric symptoms. These rates are far higher than those reported in the National 
Comorbidity Survey Replication of 9% of the adult population. These concomitant problems 
seriously threaten health, not only because it negatively impacts clinical outcomes, but also 
adherence to HIV medications [51]. In addition to physical health and well-being, HIV and 
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aging can have profound effects on the brain, making aging PLWH more susceptible to 
negative mental health outcomes such as depression, and anxiety. Our findings indicating 
that these individuals with dual or triple comorbidity are more likely to be hazardous alcohol 
users and suggest that the underlying mechanisms of these disorders are the same or are 
highly overlapping.
In this article, we have uncovered one common mechanism mediating maintenance of 
hazardous alcohol use, and stress: BDNF. Our observation is consistent with recent studies 
demonstrating that the brain stress systems, particularly the CRF pathway, play an important 
role in the maintenance of HAU. Studies have shown that chronic alcohol exposure alters 
the density of dendritic spines in the amygdala [33,52,53]. BDNF-Arc signaling pathway has 
been postulated to mediate the spine density changes that heightened greater alcohol intake 
[52]. BDNF may be particularly important, as it is a key regulator of both dopamine and 
serotonin pathways, which regulates both drinking behaviors as well as responses to 
emotionally salient triggers. These findings are highly relevant for PLWH, given that 
negative moods and alcohol use disorders play a prominent role in the clinical presentation 
of the disease, and may cause a disruptive impact on the quality of life of the affected 
subjects.
Our study also highlights the importance of gender analyses given different drinking, BDNF 
and even HIV profiles. For example, despite similar age, women have been living longer 
with HIV, they have a shorter story of drinking, yet their drinking profiles are getting closer 
to those of males. Gender differences in alcohol consumption were more notable for 
quantity rather than frequency. Since studies have indicated that older individuals tended to 
have lower BDNF levels it will be important to closely follow-up with these individuals as 
increased aging of the brain will aggravated these problems [54–56].
Nevertheless, our results have some limitations: First, a short time follow-up has reduced 
our capacity to perform more detail analyses. Second, the study design did not allow us to 
generalize study findings as our population was limited to those living in South Florida. 
However, the sample reflects the epidemiology of those around the United States. Despite 
these limitations the high prevalence of mood comorbidity and HAU in this population 
underscores the importance of integrating mental health screenings and treatments into 
clinics that provide services for PLWH. These results indicate that health care providers 
must be attentive for signs of hazardous alcohol use among subjects with multiple mood 
disorders. Our findings emphasize the need for additional research focused on BDNF. 
Notably, antidepressants including serotonin re-uptake medications did not demonstrate any 
effect, indicating that other types of pharmacological interventions need to be developed and 
tested.
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Figure 1. 
A proposed model of the interplay between Mood Alcohol and BDNF status among people 
living with HIV.
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Table 1
Sample Characteristics.
Variable HAU N=200 Non-HAU N=200 P value
Age (Years) 43 ± 6.4 41 ± 6 0.7
Gender
Men 67% 60% 0.1
Women 33% 40%
Race/Ethnicity
African American 70% 66%
0.4Black Caribbean 2% 4%
Hispanic 22% 23%
White 6% 7%
Annual Income:
Less than $10,000 88% 86%
0.7$11,000–$20,000 8% 10%
$20,000–$49,000 2% 2%
>$50,000 2% 2%
Education (years of school) 11.5 ± 2 11.3 ± 2.4 0.1
Albumin mg/dl 4 ± 0.4 4.1 ± 0.5 0.9
CD4 cell Counts 408 ± 259 455 ± 310 0.1
Viral Load Log 2.7 ± 1.3 2.6 ± 1.3 0.4
Note: Demographic characteristics were expressed as percentages by HAU groups. Biological measures were presented as means and standard 
deviations
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Table 2
Stress and Alcohol Profile.
Variables Non Stressed 1st quartile Mild Stressed 2nd Quartile
Severe Stressed 3th 
Quartile P value
Years living with HIV 16.6 ± 7.2 15.3 ± 7.7 14.1 ± 7.5 0.04
Years Drinking 6.0 ± 1.3 8.1 ± 1.2 7.2 ± 1 0.4
Past Drinking/week 8.3 ± 1.9 11.3±1.7 12.9 ± 1.6 0.07
Baseline Total Drinking/week 11.4 ± 2.6 18.4 ± 3.3 19.9 ± 2.5 0.01
Number of Drinks/day 2.9 ± 0.4 4.2 ± 0.5 5.1 ± 0.5 0.002
Number of Days per Week Drinking 2.2 ± 0.3 2.8 ± 0.3 3.3 ± 0.3 0.02
Values are means ± SD or percentages
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